- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05693545
GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial
Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent Rheumatic Heart Disease: A Non-inferiority Randomized Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
GOALIS is a randomized controlled trial developed to provide high quality contemporary evidence on the efficacy of oral penicillin as RHD prophylaxis.
Aim 1: To compare the proportion of children aged 5-17 years with latent RHD receiving oral penicillin prophylaxis who progress to worse valvular disease at 2-years compared to children who receive IM penicillin prophylaxis.
Aim 2: To evaluate the economic equivalence and cost-effectiveness of oral penicillin compared to IM penicillin, after echocardiographic screening for latent RHD detection.
Aim 3: Compare patient-reported outcomes (treatment acceptance, treatment satisfaction, and health-related quality of life) between children receiving oral and IM penicillin prophylaxis.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Mary Banks
- Email: mary.Banks@cchmc.org
Study Contact Backup
- Name: Ndate Fall, MS RN
- Phone Number: 15135171327
- Email: ndate.fall@cchmc.org
Study Locations
-
-
-
Kampala, Uganda
- Recruiting
- Uganda Heart Institute
-
Contact:
- Emmy H Okello
- Phone Number: +256775522284
- Email: emmyoks@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Has a new diagnosis of latent RHD detected through primary or secondary school echocardiographic screening.
- Has agreed to participate in the study via the study's informed consent/assent process.
Operational Definition of Latent RHD Borderline RHD or Mild Definite RHD (to include no more than mild regurgitation at the mitral or aortic valve, normal mean mitral and aortic valve gradients, normal bi-ventricular function) according to the 2012 WHF consensus criteria.
Exclusion Criteria:
- Known history of ARF or RHD
- Newly diagnosed RHD by echo screening considered to be "missed clinical RHD" as compared to true latent RHD including: > mild pathological valvular regurgitation at the mitral valve or aortic valve, mitral stenosis (mean MV gradient ≥ 4mmHg) (definite B61), aortic stenosis (mean AV gradient ≥ 20mmHg)
- Structural or functional cardiac defects, other than those consistent with RHD, that were known prior to or detected through echo screening (except patent foramen ovale, small atrial septal defect, small ventricular septal defect, small patent ductus arteriosus)
- Self-report of prior allergic reaction to penicillin
- Any known conditions predisposing to thrombocytopenia or hypercoagulability, or other contraindications to intramuscular injection
- Any known co-morbid conditions (ex. HIV, renal deficiencies, severe malnutrition) that have resulted in prescription of regular antibiotic prophylaxis)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oral Pencillin
Oral phenoxymethyl penicillin (Pen V) prophylaxis 250mg twice daily.
|
Prophylaxis
Other Names:
|
Active Comparator: IM Penicillin
Intramuscular benzathine benzylpenicillin G (BPG) prophylaxis (600,000 IU for children <30kg, 1.2 million IU for children ≥30kg), every 28 days
|
Prophylaxis
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression
Time Frame: 2 year endpoint
|
Progression of echocardiographic features of latent RHD to borderline to definite, or definite to mild or definite to moderate/severe
|
2 year endpoint
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demonstrate non-inferior costs and cost-effectiveness of oral penicillin compared to IM penicillin
Time Frame: baseline, 6, 12, 18, 24 months post randomization
|
The aim is to understand the costs and effectiveness of the intervention.
Costs will include intervention and disease specific costs, capturing both health system and family out of pocket costs.
Participants will complete a questionnaire asking about out-of-pocket cost (medications, supplies, consultation fees) and lost productivity (including missed school and workdays) due to the intervention.
Costs will be measured in the local currency (Uganda Shillings) and presented in United States dollars (USD)
|
baseline, 6, 12, 18, 24 months post randomization
|
Obtain cost data associated with the receipt of oral or IM penicillin in the community from a healthcare provider perspective.
Time Frame: 2 year endpoint
|
In order to understand health center and community costs, 10 randomly selected health care facilities (including level II, III, and IV facilities) will be surveyed to obtain direct costs of medications, supplies as well as any administration and professional fees associated with outpatient and inpatient visits.
|
2 year endpoint
|
Treatment Acceptance
Time Frame: baseline, 6, 12, 18, 24 months post randomization
|
Treatment acceptance will be assessed with the widely-used Chronic Treatment Acceptance (ACCEPT) questionnaire, a generic medication acceptance instrument validated for chronic conditions.
This 25-item survey consists of six areas of focus: medication convenience (3 items), length of treatment (2 items), medication constraints (9 items), medication side effects (5 items), medication effectiveness (3 items), medication advantages (3 items).
Responses are rated on a 5-point Likert scale and scores of 1 through 4 indicating increasing levels of acceptance.
|
baseline, 6, 12, 18, 24 months post randomization
|
Treatment Satisfaction
Time Frame: baseline, 6, 12, 18, 24 months post randomization
|
Treatment Satisfaction will be assessed with the 14-item Abbreviated Treatment Satisfaction Questionnaire (v 1.4).
This widely used survey contains 4 areas of focus including satisfaction of treatment effectiveness (3 items), satisfaction with treatment side effects (5 items), satisfaction with treatment convenience (3 items), and a global treatment satisfaction (3 items).
Scores are then transformed to a score of 0-100 to create the overall scale score and the subcategory scores, with higher scores representing higher treatment satisfaction on that domain.
|
baseline, 6, 12, 18, 24 months post randomization
|
Health-Related Quality of Life
Time Frame: baseline, 6, 12, 18, 24 months post randomization
|
Health Related Quality of Life will be measured using the Pediatric Quality of Life Inventory Version 4.0 Generic Core (PedsQL 4.0) questionnaire.
The PedsQLTM4.0 is a 23-item survey for children aged 5-18 which assesses HRQOL.
It has four areas of focus: Physical functioning (8 items), emotional functioning (5 items), social functioning (5 items), school functioning (5 items).
Each item has five possible responses measuring the extent to which the item was a problem during the past month.
The possible responses are measured using a 5-point Likert scale from 0=never a problem to 4 = almost always a problem.
These reverse scaled scores are then transformed to a score of 0-100 to create the overall scaled score and the subcategory scores, with higher scores representing better quality of life.
|
baseline, 6, 12, 18, 24 months post randomization
|
Patient-reported outcomes
Time Frame: baseline, 6, 12, 18, 24 months post randomization
|
Interviews will be used to collect qualitative data around participants perceptions of the impact of RHD and its treatment on their activities of daily living and quality of life including experiences with IM or oral penicillin prophylaxis.
|
baseline, 6, 12, 18, 24 months post randomization
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Andrea Z Beaton, Cincinnati Chidren's hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Infections
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Streptococcal Infections
- Gram-Positive Bacterial Infections
- Rheumatic Fever
- Heart Diseases
- Rheumatic Diseases
- Rheumatic Heart Disease
- Anti-Infective Agents
- Anti-Bacterial Agents
- Penicillins
- Penicillin G Benzathine
- Penicillin G
- Penicillin G Procaine
- Penicillin V
Other Study ID Numbers
- 2022-0892
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatic Heart Disease
-
Children's National Research InstituteUniversity of Cape Town; Thrasher Research Fund; Murdoch Childrens Research Institute and other collaboratorsUnknownHeart Diseases | Rheumatic Heart Disease | Rheumatic Heart Disease in Children | Latent Rheumatic Heart DiseaseUganda
-
Assiut UniversityCompletedRheumatic; Heart Disease, Maternal, Affecting Fetus
-
Paris Cardiovascular Research Center (Inserm U970)Not yet recruitingRheumatic Heart Disease in Children
-
University Hospital Inselspital, BerneRecruitingRheumatic Heart Disease | Rheumatic Heart Disease in ChildrenNepal
-
Beijing Anzhen HospitalRecruitingOutcomes of Mitral Valve Surgery in Patients Affected by Rheumatic Heart DiseaseChina
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI); Manmohan Cardiothoracic...Active, not recruitingRheumatic Heart Disease | Valvular DiseaseNepal
-
University Hospital Inselspital, BerneInstituto de Cardiología Paredes-Horna, Arequipa; Hospital Nacional Carlos...CompletedRheumatic Heart Disease | Acute Rheumatic FeverPeru, Switzerland
-
Assiut UniversityCompletedRenal Dysfunction | Cardiac Surgery for Rheumatic Valvular Heart DiseaseEgypt
-
National Human Genome Research Institute (NHGRI)CompletedAcquired Heart Disease | Rheumatic Heart Disease | Rheumatic Fever | Endomyocardial FibrosisUganda, Nigeria
-
Assiut UniversityNot yet recruitingHeart Failure | Rheumatic Heart Disease
Clinical Trials on phenoxymethyl penicillin
-
Imperial College LondonCompleted
-
Drugs for Neglected DiseasesUnknownChagas Disease | Trypanosomiasis, South American | South American Trypanosomiasis | Disease, ChagasBolivia
-
Imperial College LondonRecruiting
-
PfizerCompleted
-
KEMRI-Wellcome Trust Collaborative Research ProgramLondon School of Hygiene and Tropical Medicine; University of Oxford; University...Completed
-
Jun LiUnknown
-
Children's National Research InstituteUniversity of Cape Town; Thrasher Research Fund; Murdoch Childrens Research Institute and other collaboratorsUnknownHeart Diseases | Rheumatic Heart Disease | Rheumatic Heart Disease in Children | Latent Rheumatic Heart DiseaseUganda
-
Peking Union Medical College HospitalUnknown
-
University of Southern CaliforniaUniversidad Peruana Cayetano Heredia; AIDS Healthcare FoundationRecruiting
-
National Institute of Allergy and Infectious Diseases...Completed